×
Our science-based antibodies and antigens can be a crucial piece of patient diagnostics. While there are still open questions about the clinical value of each marker and practice, step-by-step, we’re solving the diagnostic mystery of neurodegeneration caused by either trauma or diseases.
This year, we launched the NfL, which is a promising marker, and we’ll soon be finalizing the S100 protein analysis. These novelties, side-by-side, with the other neuroscience markers, provide us with new data enabling the use of our markers for assay development and the faster diagnosis of the diseases.
Evaluate
Neuroscience MAbs
already today!
Read more and
order below >>
Neurofilament light (NfL)
NfL is a neuronal cytoplasmic protein that exists in axons. The concentration of NfL in cerebrospinal fluid (CSF) and blood correlate with the degree of axonal damage.
Read more >>
Beta-amyloid, human
Beta-amyloid, which is also referred to as Aβ, is a peptide that is derived from the amyloid precursor protein. It is one of the most established biomarkers for the progression of Alzheimer’s disease (AD).
Read more >>
Glial fibrillary acidic protein (GFAP)
GFAP is an astrocyte structural protein. GFAP has been authorized as one of the biomarkers for mild traumatic brain injury (mTBI) and its level shows a correlation with the clinical severity after the injury.
Read more >>
S100 proteins
S100 proteins are synthesized in astroglial cells and can be used as sensitive and reliable markers for central nervous system damage.
Read more >>
Others:
Cat# 4N6: Neuron-Specific Enolase, Human, antibody
Copyright © HyTest Ltd.